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This paper presents the first full micro costing of a commonly used cancer genetic counselling and testing protocol used in the UK.
Costs were estimated for the Cardiff clinic of the Cancer Genetics Service in Wales by issuing a questionnaire to all staff, conducting
an audit of clinic rooms and equipment and obtaining gross unit costs from the finance department. A total of 22 distinct event
pathways were identified for patients at risk of developing breast, ovarian, breast and ovarian or colorectal cancer. The mean cost per
patient were d97–d151 for patients at moderate risk, d975–d3072 for patients at high risk of developing colorectal cancer and
d675–d2909 for patients at high risk of developing breast or ovarian cancer. The most expensive element of cancer genetic services
was labour. Labour costs were dependent upon the amount of labour, staff grade, number of counsellors used and the proportion of
staff time devoted to indirect patient contact. With the growing demand for cancer genetic services and the growing number of
national and regional cancer genetic centers, there is a need for the different protocols being used to be thoroughly evaluated in
terms of costs and outcomes.
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For over a century clinicians have been aware that a hereditary
predisposition to develop cancer exists in certain families (Steel
et al, 1999). In total, 5% of breast cancer cases are believed to be
due to inherited genetic mutations (Lynch et al, 1984); 10–11.7%
of ovarian cancer cases (Landis et al, 1999; Risch et al, 2001;
Malanders et al, 2004) are believed to be the result of breast cancer
susceptibility one and two (BRCA1/2) mutations (Miki et al, 1994;
Wooster et al, 1995). The hereditary genetic disorders of
nonpolyposis colorectal cancer (HNPCC) and familial adenoma-
tous polyposis coli (FAP or FAPC) are believed to be responsible
for 2–7 and 1% of colorectal cancer cases, respectively (Soravia
et al, 1997; Aaltonen et al, 1998).
With the availability of commercial genetic testing and the
development of regional cancer genetics clinics in England, and
national services in Wales and Scotland, physicians can now refer
families to ascertain their genetic risk. Despite a burgeoning
literature upon the psychosocial impact of familial cancer and
accessing genetic services upon patients (Audrain et al, 1998;
Lerman et al, 1998; Brain et al, 2000; Clarke et al, 2001; Geer et al,
2001; Rees et al, 2001; Fry et al, 2003), full and partial economic
evaluations of cancer genetic services are sparse (Griffith et al,
2004). In this paper, we present the first full micro costing of a
commonly used cancer genetic counselling and testing protocol
used in the UK with patients at increased risk of developing breast,
ovarian, breast and ovarian (breast ovarian) or colorectal cancer.
The micro costing was conducted at the Cardiff clinic of the Cancer
Genetics Service in Wales (CGSW) as part of a multimethod
evaluation of that service by the GenQuest research team.
Figure 1 illustrates the service provided to patients referred to
the CGSW. Primary, secondary and tertiary care clinicians
throughout Wales have been issued with referral guidelines to
aid them in assessing whether or not a patient should be referred
to cancer genetic services (See Table 1). Once a patient is referred,
they are issued by post with a general information pack on genetic
cancer and a questionnaire asking them about their family history
of cancer. If the questionnaire is not returned within 4 weeks, a
reminder letter is issued. Upon receipt of a completed family
history questionnaire, a risk assessment is carried out. Cyrilic
software is used to establish the patient’s risk of developing cancer;
all patients will either be at high, moderate or population risk. All
high and moderate risk patients, with the exception of those at
moderate risk of developing breast cancer, then have their family
history checked against medical records. Finally, all four
counsellors (team leader, service and practice development
coordinator and two consultants, see Table 2 for staff) will discuss
the patient’s family history, confirm the risk status and the most
appropriate care for the patient.
In the case of an inappropriate referral, a patient believed to be
at increased risk (moderate or high) due to their self-reported
family history but subsequently found to be at population risk
following examination of medical records and risk assessment, the
general practitioner (GP) and referrer are informed. The GP and/or
referrer contact the patient, reassure them that they are at
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spopulation risk and advise them to adhere to general health
awareness measures and to attend national screening programmes
when they are eligible.
All moderate risk patients are telephoned and informed of their
risk status by the team leader or service and practice development
coordinator. Patients at moderate risk of developing breast or
colorectal cancer are encouraged to discuss any fears and
questions they have and receive counselling over the phone at a
time that is convenient for them. Patients at risk of developing
ovarian or breast ovarian cancer are also contacted by phone but
are invited to come to the clinic for a face to face counselling
session with a counsellor (team leader, service and practice
development coordinator or consultants [MC21/02]). Following
counseling, breast, ovarian and breast ovarian patients are referred
by the genetics service and colorectal patients by their GP/referrer
for presymptomatic care.
All high-risk patients are informed over the phone by a genetic
counsellor (team leader, service and practice development
coordinator or consultants [MC21/02]) that they are at high risk
and are invited to come to the clinic for a counselling session. The
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Patients are  
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Figure 1 Overview of care provided to patients.
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spreliminary counselling session includes a full discussion of the
implications, issues and procedures involved in genetic testing and
presymptomatic care. As confronting the issues associated with
genetic disease can induce psychological distress among some
patients (Lerman et al, 1997; Grosfeld et al, 2000; Fry et al, 2003),
they are reminded that they are free to withdraw from genetic
testing at any time. For patients who wish to proceed with genetic
testing, a living cancer-affected relative is then invited to come to
the genetics clinic for counselling and to have a blood sample
taken for genetic testing. While the cancer-affected relative’s blood
is being tested, the presymptomatic patient will give blood and
attend counselling twice with a minimum of a 1 month interval
between both visits. Two blood samples are taken on separate
visits to minimise the possibility of identification errors occurring
in relation to blood/DNA samples. A 1 month interval between the
counselling sessions is used to allow time for patients to consider
the implications of testing and ask further questions. This
counselling protocol is derived from the highly successful
Huntington’s protocol developed at the Institute of Medical
Genetics in Cardiff. During counseling, presymptomatic patients
are prepared for the possibility that they have an established
mutation predisposing them to develop cancer, there is a mutation
in their family but they have not inherited it (however, a close
relative may have inherited the mutation) or that their family does
not have an established mutation but their family history suggests
that their family have an as yet unidentified mutation. In the
former and latter cases, presymptomatic patients are referred for
presymptomatic care. In the penultimate case, patients are
reassured that they are at population risk and advised to adhere
to general health awareness measures and to attend national
screening programmes when they become eligible.
Molecular genetic testing for mutations predisposing patients to
develop cancer currently comprises of conducting mutation
screening and presymptomatic testing by means of sequence
analysis. A screening test is the first test conducted for a high-risk
family; a cancer-affected relative is tested for a breast, ovarian,
breast ovarian, HNPCC or FAP mutation. In the case of breast and/
or ovarian cancer, the Cardiff laboratory conducts full mutation
screening of all 22 relevant exons (45 fragments) of the BRCA1
gene and all 26 relevant exons (40 fragments) of the BRCA2 gene
for a cancer-affected relative. Exons of the BRCA1 gene are
prescreened by Denaturing Gradient Gel electrophoresis (DGGE)
and electrophoretic variants are sequenced in both directions to
determine the nature of the DNA sequence variant and therefore
whether it is responsible for the inherited breast/ovarian cancer in
that family (i.e. it is pathogenic). Similarly, exons of the BRCA2
gene are prescreened by Denaturing High Performance Liquid
Chromatography (DHPLC); variants are again further assessed by
bidirectional sequence analysis. For HNPCC, 19 exons (19
fragments) of the MLH1 and 16 exons (16 fragments) of the
MSH2 genes are searched. For FAP, 15 exons (24 fragments) of the
APC gene are fully searched. The MLH1, MSH2 and APC genes are
screened directly by bidirectional sequence analysis, thus the
pathogenicity of variants is directly determined.
Presymptomatic testing (PST) is provided to relatives of a
cancer-affected patient that has been found to be a mutation
carrier by a mutation screening test. Presymptomatic testing is
conducted upon the BRCA1, BRCA2, MLH1, MSH2 and the APC
genes by bidirectional sequence analysis of duplicate DNA samples
from the at risk relative alongside a control sample from the
cancer-affected patient in which the familial pathogenic mutation
has previously been identified. In the past, patients suspected of
having an APC mutation predisposing them to FAP and with a
suitable family structure were identified by means of linkage
analysis. Linkage analysis is being phased out in Cardiff but has
been included in this paper as it may still be in use in some small
regional laboratories.
For information purposes we include below the presymptomatic
care that patients are referred for by the cancer genetics service.
Presymptomatic care in not costed in this paper, only the capital,
labour and overheads used in referring a patient for presympto-
matic care are included in the costing. Presymptomatic care
for patients at increased (moderate and high) risk of developing
cancer includes surveillance and/or prophylactic surgery.
Table 1 Referral guidelines
Cancer Family history criteria (on the same side of the family)
Breast cancer K One first-degree relative diagnosed at 40 years or less.
K Two first-degree relatives diagnosed at 60 years or less.
K Three first- or second-degree relatives diagnosed at any age.
K One first-degree male breast cancer.
K A first-degree relative with bilateral breast cancer.
Breast/ovarian cancer K At least one breast and one ovarian cancer in first-degree relatives (breast cancer diagnosed under 50 years if only one of each cancer).
K A first-degree relative who has both breast and ovarian cancer.
Ovarian cancer K Two or more ovarian cancers (at least one first-degree relative).
Colon cancer K One first-degree relative diagnosed at 40 years or less.
K Two first-degree relatives diagnosed at 60 years or less.
K Three relatives diagnosed at any age (at least one first-degree relative).
K Familial adenomatous polyposis in a first- or second-degree relative.
K Hereditary nonpolyposis colorectal cancer (revised Amsterdam criteria) in a first- or second-degree relative.
Table 2 Staff and grades
Title Grade
Proportion of time
working for the service
Gross wages
per hour
Administrative assistant CR31/05 1.0 d11.19
Administrative assistant CR31/03 0.07 d10.32
Consultant MC21/04 1.0 d51.86
Consultant MC21/02 0.6 d45.46
Coordinator CR31/03 0.4 d10.32
Team leader NPU/04 1.0 d22.10
Genetic technologist MT01 0.1 d8.97
Genetic technologist MT02 1.0 d10.54
Principal clinical scientist B-grade 17 1.0 d19.96
Service and practice
development coordinator
NP51/05 0.8 d20.41
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sSurveillance for women at increased risk of developing breast
cancer is provided in the form of annual mammography from the
age of 35 (high risk)/40 (moderate risk) to 50 years and every 18
months from 50 to 60 years of age. At 60 years, women enter the
national screening programme and receive mammography every 3
years. The alternative to surveillance is to have prophylactic
surgery in the form of bilateral prophylactic mastectomy,
oophorectomy with mammography or both surgeries. Patients at
increased risk of developing colorectal cancer (HNPCC or FAP)
receive a combination of surveillance and surgery; colonoscopy
every 2 (high risk)/5 (moderate risk) years and polypectomy as
required. Surveillance commences at 5 years prior the youngest
cancer incidence in the family, with a minimum age of 20 years for
high-risk patients and 25 for moderate risk patients. Alternatively,
patients can opt for the prophylactic surgery options of subtotal
colectomy or protocolectomy. Women at increased risk of
developing ovarian cancer have the surgical option of having
prophylactic oophorectomy. Women at increased risk that are
referred to the CGSW can have presymptomatic surveillance
despite the fact that there is currently no evidence-based
surveillance strategy for them. Surveillance is provided as part of
the UK Familial Ovarian Cancer Screening Study (UKFOCSS)
(Jacobs et al, 2000), which is seeking to develop an optimised
screening procedure for these women. Women opting to
participate in the UKFOCSS study are asked to attend a joint
consultation between the genetics service and a consultant surgeon
(all patients at increased risk can (colorectal will) see a surgeon
and/or oncologist as part of their presymptomatic care but a
genetic counsellor will not be present). This involves a 10–15min
consultation for moderate risk women and 10–30min consultation
for those at high risk. Surveillance is in the form of annual
ultrasound of the ovaries and CA125 blood testing from the age of
35 years. All costs associated with the UKFOCSS research project
have been excluded from the costs that follow in Tables 5 and 9.
Women at increased risk of developing breast ovarian cancer are
offered the same presymptomatic care as women at increased risk
of breast and women at increased risk of ovarian cancer.
MATERIALS AND METHODS
Establishing from the provider’s perspective, the cost per patient of
providing cancer genetic services comprised of four main steps:
1. Identifying all event pathways that have resource or clinical
outcomes for patients.
2. Measurement of the resources required for each event pathway.
3. Establish the cost per unit of resource.
4. Apply the cost of the resources used to each event pathway.
All event pathways and all of the distinct stages associated with
the pathways were identified from service protocols and consulta-
tion with the team leader and senior consultant at the clinic. In
2002, the clinic had seven members of clinical and administrative
staff and a further three laboratory staff (see Table 2). Labour
capital and overhead resources were measured by means of a
questionnaire administered to all members of staff and conducting
an audit of the clinic rooms and laboratory. Clinical and
administrative staff were asked to report on average how long a
procedure took them in minutes, the typical quantity of
consumables used, to list any equipment used and where each
task was undertaken. Laboratory staff were asked what elements of
molecular genetic testing they conducted, which equipment was
used, which consumables were used and to estimate any wastage,
for example spillage etc.
The finance department of the Cardiff and Vale NHS trust was
asked to provide costs for staff time, capital, overheads, equipment
and consumables. Staff time was valued at actual gross wage rates
including National Insurance and pension contributions adjusted
for holiday and sick leave. Capital charges for buildings were taken
from the annual value assigned by the district valuer. Consumables
and equipment were valued at replacement cost.
Having ascertained which steps of an event pathway each
member of staff participated in, which rooms were used (including
50% of communal facilities shared with the remainder of the
Medical Genetics Service in Wales) and resources required, this
information was combined with the information gained from an
audit of the furniture and equipment in each room of the clinic to
produce an inventory of the rooms and equipment associated with
each task. Equipment costs were transformed into an annual cost
assuming a 6% discount rate, a 5 year working life and payment in
arrears. In addition to annual equipment costs, each room was
allocated in terms of total area, a proportion of the annual capital
charge, rates, maintenance costs, cleaning, and power and
sewerage charges. Laboratory rooms also had the costs associated
with laboratory refuse and maintenance of specialist equipment.
Total room costs were then calculated for the number of hours
annually that they are allocated to the cancer genetics service
allowing for holiday and sick leave. As rooms that were not used
100% of the time by the cancer genetics team were used for the
remainder of the time by other genetics services such as
Huntington’s disease fixed costs were fully accounted for.
Using the Committee for Medical Genetics Workload Units
Working Group report (2002), each task undertaken by a member
of the laboratory staff was transformed into work load units
(WLUs). Essentially, a workload unit represents the laboratory and
administrative operations completed in a minute (including
indirect time such as clinical governance and professional
development). As WLUs are applicable to all laboratories in the
UK, they have been calculated based upon the minimum batch size
and technology representative of small laboratories; however, they
can be modified to account for the use of semiautomated
technology which is generally employed when screening large
genes for unknown mutations. An allowance for medium
throughput technology was applied in this study. Based on
laboratory records it was possible to ascertain the annual WLUs
completed by all laboratory staff in the last 12 months and
calculate gross labour costs per WLU and hour.
During administration of the questionnaire to staff it emerged
that in addition to the direct time spent in contact with patients
and processing their referrals, a wide range of other commitments
which recur but are sporadic in terms of timing, and contribute to
the workload of staff were cited by clinical, laboratory and
administrative staff. These included:
Administrative
  Meeting with surgeons to discuss the appropriateness of their
referrals.
  Audit, clinical governance and administrative requests.
  Attendance at trust meetings.
  Team management.
Education and development
  Formal teaching and contributing to conferences.
  Personal education and skills development.
  Facilitating and participating in research.
Estimates of the amount of time that went on indirect work
varied between 25 and 75%. To take these commitments into
account, 33% of work time was assumed to be devoted to indirect
patient contact and labour costs for clinical and administrative
staff were inflated accordingly. It was not necessary to do this for
the laboratory staff as WLUs already contain an inflation to take
account of these additional time commitments.
Annual stationary, photocopying, postage and telephone charges
plus courses and training costs were transformed to a cost per
hour per WLU based on the total number of hours per WLUs per
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syear each member of staff using each resource worked. Costs are
presented in 2002/2003 pounds. As capital and overhead costs were
measured in 2001/2002, these costs were inflated to 2002/2003
levels using the Hospital and Community Pay and Price Index
(Netten and Curtis, 2003).
RESULTS
A total of 22 distinct event pathways were identified in this study
(see Table 3). Event pathway one represents a patient referred to
the cancer genetics service but deciding not to proceed with the
referral by not returning the family history questionnaire. The
patient will have been issued with a reminder letter 4 weeks after
they were issued with the questionnaire. Event pathway two
represents an inappropriate referral; a patient believed to be at
increased risk due to their self-reported family history but
subsequently found to be at population risk following examination
of medical records and risk assessment (left hand column of
Figure 1). Event pathways three to five are the moderate risk event
pathways (centre column of Figure 1). Event pathways six to 22 are
the high-risk event pathways (right hand column of Figure 1).
Event pathways 6, 10, 15 and 19 represent high-risk families
approaching the cancer genetics service for the first time. Having
tested and found a known mutation, for example, mutated BRCA2
or MLH1, the first presymptomatic family member to approach the
service (usually the patient originally referred to the genetics
service) is tested.
Event pathways 7, 11, 16 and 20 represent families where the
cancer-affected relative is tested and no known mutation is found.
The presymptomatic patient and his/her first-degree relatives (e.g.
sister, mother or daughter) are still at high risk due to their family
history. It is likely that these families have mutations that have yet
to be identified by genetic scientists. The presymptomatic patients
in these event pathways are dealt with in exactly the same way as
patients with a known mutation such as MLH1 in their family,
except they do not receive genetic testing.
Event pathways 8, 13, 17 and 21 represent the second and any
subsequent presymptomatic family members of a family where a
cancer-affected relative has been found to have a known mutation.
These event pathways only contain the costs associated with
testing, counselling and referring for presymptomatic care each
presymptomatic patient deciding to approach the cancer genetics
service. Event pathway 12 is the forerunner of event pathway 13
and is becoming obsolete. In this event pathway linkage testing is
used rather than sequence analysis to identify an APC mutation.
Linkage testing is a less sensitive method of testing and requires a
suitable family structure.
Event pathways 9, 14, 18 and 22 represent the second and
subsequent family members of a high-risk family where no known
mutation was found when testing a cancer-affected relative.
Presymptomatic patients in this event pathway are dealt with in
exactly the same way as patients from families with a known
mutation, except that they do not receive genetic testing.
The number of event pathways, number of possible staff
combinations within each pathway and the number of distinct
steps in each pathway prohibit displaying all the clinical and
administrative labour associated with each pathway. Table 4 is an
example of the clinical and administrative resources required for
event pathway 5, moderate risk – ovarian or breast ovarian cancer.
Clinical and administrative consumables are not listed as they were
all part of the overhead cost, for example, stationary (all sources of
capital and overhead costs are listed in the Materials and Methods
section).
In Table 5, we present the clinical and administrative costs of the
cancer genetics service in terms of labour, capital and overhead
costs (all consumables were included in the overhead costs).
Labour formed the majority of the cost for each event pathway. In
the case of a patient who does not return their family history
questionnaire (event pathway 1), 61% of the mean cost was labour,
23% capital and 16% overheads. The division for an inappropriate
referral and the moderate risk event pathways (event pathways
2–5) was 68–70% labour, 17–18% capital and 12–13% overhead.
In all, 70–72% of the clinical and administrative cost of high-risk
breast cancer event pathways (event pathways 15–18) was labour,
17–19% capital and 11% overheads. For the ovarian/breast
ovarian and colorectal event pathways (6–9, 10–14 and 19–22),
labour costs amounted to 75–78%, capital 13–15% and overheads
10%.
Tables 6 and 7 present the tasks, resources and consumables
required for each molecular testing strategy. In Table 8, the cost of
these strategies is presented in terms of capital, overhead and
consumable costs. As was the case for clinical and administrative
costs, the largest component of the costs was labour. In all, 59–
63% of all presymptomatic tests (Sequence analysis and linkage
analysis) were labour costs, 8–13% consumables, 20% capital and
9% overheads. A total of 53% of mutation screening for breast and
breast ovarian mutations was labour, 13% consumables, 23%
capital and 11% overheads. While the largest element of mutation
screening for a HNPCC or FAP mutation was labour costs, it
amounted to a substantially lower percentage than seen for the
other mutation screening tests at 38%. Laboratory consumables
costs formed a large element of mutations screening costs for
HNPCC and FAP at 28%, 15% higher than for any other test;
capital and overhead costs, respectively, amounted to 23 and 11%
of the total cost.
Table 9 contains the minimum costs, maximum costs and their
mean for all the breast, ovarian/breast ovarian and colorectal
cancer risk categories dealt with by the CGSW. An initial referral
where the patient decides not to proceed and does not return their
family history questionnaire (event pathway 1) resulted in a mean
cost of d16. For a patient at moderate risk of breast or colorectal
cancer or an inappropriate referral (event pathways 2, 3 and 4), the
mean cost was d97–d98. The cost of dealing with a woman at
moderate risk of developing ovarian or breast ovarian cancer was
the highest of all the moderate risk pathways at d151.
The cost of counselling, testing and referring the first high-risk
presymptomatic member of a family and a caner-affected relative
(event pathways 6, 10, 15 and 19) for breast, ovarian/breast ovarian
or colorectal cancer (HNPCC or FAP) ranged between d2510 and
d3072. In the event of no established mutation such as BRCA1
being found when a cancer-affected relative is tested, the cost of
testing the cancer-affected relative, counselling and referring the
cancer-affected relative and the presymptomatic relative (event
pathways 7, 11, 16 and 20) ranged between d1665 and d2039. The
cost of genetically testing, counselling and referring any members
of a family where a mutation had previously been found (event
pathways 8, 12, 13, 17 and 21), for example, a brother or sister and
a cancer-affected relative had been through event pathways 6, 10,
15 or 19, ranged between d1,152 and d1,589. The cost of
counselling and referring subsequent members of a family where
testing had revealed that there was no known mutation such as
BRCA2 but their family history placed them at high risk ranged
between d675 and d975 (event pathways 9, 14, 18 and 22).
Sensitivity
To assess the sensitivity of the total cost of each event pathway to
the amount of time devoted by clinical and administrative staff to
indirect patient contact, the minimum and maximum reported
percentages of indirect work time, 25 and 75% were substituted
into the labour costs (see final and penultimate columns of
Table 9). Given that the largest element of the cost of each event
pathway was labour (see Tables 5 and 8), it is not surprising to find
that the total cost per event pathway was sensitive to change in the
percentage of indirect working time. Assuming 25% of working
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stime to be indirect rather than the 33% used in the base case
resulted in costs declined for all event pathways to 87–95% of the
means base case costs, for example, Event pathway 1, d13.47/
d15.54*100¼87%. Assuming 75% of work time to be devoted to
indirect patient contact resulted in costs rising to 167–267% of the
base case, for example, Event pathway 1, d41.44/
d15.54*100¼267%. The event pathways with no laboratory
testing, event pathways 1–5, 9, 14, 18 and 22, were most sensitive
Table 3 Event pathways
1. Family history questionnaire not returned
2. Inappropriate referral
3. Moderate risk – breast cancer
4. Moderate risk – colorectal cancer
5. Moderate risk – ovarian or breast ovarian cancer
High risk – colorectal (HNPCC)
6. Test cancer-affected relative (mutation found) and test presymptomatic patient
7. Test cancer-affected relative (no mutation found) and do not test presymptomatic patient
8. Test subsequent presymptomatic members of a family with an established mutation
9. Counsel and arrange presymptomatic care for members of a family with no established mutation
High risk – colorectal (FAP)
10. Test cancer-affected relative (mutation found) and test presymptomatic patient
11. Test cancer-affected relative (no mutation found) and do not test presymptomatic patient
12. Test subsequent presymptomatic members of a family with an established mutation (using linkage testing)
13. Test subsequent presymptomatic members of a family with an established mutation (using sequence analysis)
14. Counsel and arrange presymptomatic care for members of a family with no established mutation
High risk – breast (BRCA1/2)
15. Test cancer-affected relative (mutation found) and test presymptomatic patient
16. Test cancer-affected relative (no mutation found) and do not test presymptomatic patient
17. Test subsequent presymptomatic members of a family with an established mutation
18. Counsel and arrange presymptomatic care for members of a family with no established mutation
High risk – ovarian or breast ovarian (BRCA1/2)
19. Test cancer-affected relative (mutation found) and test presymptomatic patient
20. Test cancer-affected relative (no mutation found) and do not test presymptomatic patient
21. Test subsequent presymptomatic members of a family with an established mutation
22. Counsel and arrange presymptomatic care for members of a family with no established mutation
HNPCC¼hereditary nonpolyposis colorectal cancer; FAP or FAPC¼familial adenomatous polyposis coli.
Table 4 Tasks undertaken by clinical and administrative staff for patients at moderate risk of ovarian or breast ovarian cancer
Task Time (min) Staff Resources
1. Record receipt of referral letter 1.0 Administrative assistant (CR31/05) Office
2. Input client details to database and issue family history
questionnaire
3.5 Administrative assistant (CR31/05) Office
3. Record return of family history and update database 2.0 Administrative assistant (CR31/05) Office
4. Input family history into computer 3.0–7.5 Team leader (NPUV/04) Office
5. Obtain permission to access relatives’ medical records 3.0–7.5 Team leader (NPUV/04) Office
6. Obtain records 3.0 Coordinator (CR31/03) Office
7. Check medical records 4.0–7.5 Team leader (NPUV/04) Office
8. Review family history 4.0–15.0 Team leader (NPUV/04) and service and practice
development coordinator (NP51/05) and consultant in
cancer genetics (MC21/02) and consultant in cancer
genetics (MC21/04)
Offices and
Seminar room
10. Letter and booklet to patient and letter to referrer 10.0 Administrative assistant (CR31/03) Office
11. Counselling session 50.0–60.0 Team leader (NPUV/04) or service and practice
development coordinator (NP51/05) or consultant in
cancer genetics (MC21/02)
Offices and
counselling room
12. Refer to Breast Test Wales and/or gynaecologist/
surgeon if appropriate
10.0 Team leader (NPUV/04) or service and practice
development coordinator (NP51/05) or consultant in
cancer genetics (MC21/02)
Office
13. Fill in database 5.0 Coordinator (CR31/03) Office
Communal facilities 64–97.5
a
Communal facilities include phlebotomy room (take blood), waiting room, toilets and hallways.
aTotal time devoted to a single patient by one or more members of staff minus
overlap with other patients. There are no laboratory inputs for this event pathway.
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sto change in the percentage of work time devoted to indirect
patient contact.
DISCUSSION
The variation between minimum and maximum costs within each
event pathway (Table 9) is a result of the grade of the staff that can
be involved and the variation in the time it could take to conduct
the work associated with each referral. The differences in the costs
of referrals at moderate risk of breast, ovarian and colorectal
cancer are a result of the variation in the services and work
associated with each type of referral. Usually it is not necessary to
obtain medical records for relatives of patients believed to be at
moderate risk of developing breast cancer, while this is a necessity
for ovarian/breast ovarian and colorectal referrals. The cost of
dealing with patients believed to be at moderate risk of ovarian/
breast ovarian cancer is greater than that for colorectal cancer.
This is a result of colorectal patients receiving phone counselling
for 7.5–15.0min, while ovarian patients attend the genetics clinic
for a face to face counselling session of approximately 1-h
duration. The face to face counselling and additional counselling
time devoted to women at moderate risk of developing ovarian
cancer is due to the greater uncertainty surrounding these women.
While these women can be positively identified as being at
increased risk, there is currently no evidence-based surveillance
Table 5 Counselling and administrative costs
Counselling and administrative costs
Event pathway Labour (min–max) Capital (min–max) Overheads (min–max) Total (min–max)
1. Family history questionnaire not returned d9( d9–d10) d4( d2–d5) d2( d2–d3) d16 (d14–d17)
2. Inappropriate referral d69 (d37–d100) d17 (d8–d26) d12 (d6–d18) d98 (d51–d144)
3. Moderate risk – breast cancer d66 (d27–d105) d18 (d8–d28) d13 (d6–d20) d97 (d40–d153)
4. Moderate risk – colorectal cancer d69 (d37–d100) d17 (d8–d26) d12 (d6–d18) d98 (d51–d144)
5. Moderate risk – ovarian or breast ovarian cancer d105 (d51–d158) d27 (d17–d37) d20 (d11–d28) d151 (d79–d223)
High risk – colorectal (HNPCC)
6. Test cancer-affected relative (mutation found) and test
presymptomatic patient
d1068 (d593–d1542) d188 (d111–d265) d139 (d99–d180) d1396 (d803–d1988)
7. Test cancer-affected relative (no mutation found) and
do not test presymptomatic patient
d622 (d338–d906) d119 (d70–d167) d85 (d58–d113) d826 (d466–d1186)
8. Test subsequent presymptomatic members of a family
with an established mutation (MLH1/ MSH2 mutation in
family)
d777 (d432–d1121) d125 (d77–d173) d95 (d71–d120) d997 (d579–d1415)
9. Counsel and arrange presymptomatic care for
members of a family with no established mutation
d759 (d415–d1103) d122 (d74–d171) d93 (d68–d118) d975 (d557–d1392)
High risk – colorectal (FAP)
10. Test cancer affected relative (mutation found) and
test presymptomatic patient
d1068 (d593–d1542) d188 (d111–d265) d139 (d99–d180) d1396 (d803–d1988)
11. Test cancer-affected relative (no mutation found)
and do not test presymptomatic patient
d622 (d338–d906) d119 (d70–d167) d85 (d58–d113) d826 (d466–d1186)
12. Test subsequent presymptomatic members of a
family with an established mutation (using linkage testing)
d777 (d432–d1121) d125 (d77–d173) d95 (d71–d120) d997 (d579–d1415)
13. Test subsequent presymptomatic members of a
family with an established mutation (using sequence
analysis)
d777 (d432–d1121) d125 (d77–d173) d95 (d71–d120) d997 (d579–d1415)
14. Counsel and arrange presymptomatic care for
members of a family with no established mutation
d759 (d415–d1103) d122 (d74–d171) d93 (d68–d118) d975 (d557–d1392)
High risk – breast (BRCA1/2)
15. Test cancer-affected relative (mutation found) and
test presymptomatic patient
d705 (d264–d1146) d181 (d106–d256) d110 (d67–d153) d996 (d437–d1555)
16. Test cancer-affected relative (no mutation found)
and do not test presymptomatic patient
d430 (d173–d687) d115 (d68–d162) d70 (d42–d98) d614 (d283–d946)
17. Test subsequent presymptomatic members of a
family with an established mutation
d496 (d170–d822) d119 (d73–d166) d72 (d45–d99) d688 (d288–d1087)
18. Counsel and arrange presymptomatic care for
members of a family with no established mutation
d487 (d165–d809) d117 (d70–d164) d71 (d44–d98) d675 (d279–d1070)
High risk – ovarian or breast ovarian (BRCA1/2)
19. Test cancer-affected relative (mutation found) and
test presymptomatic patient
d1068 (d593–d1542) d188 (d111–d265) d139 (dd99–d180) d1396 (d803–d1988)
20. Test cancer-affected relative (no mutation found)
and do not test presymptomatic patient
d622 (d338–d906) d119 (d70–d167) d85 (d58–d113) d826 (d466–d1186)
21. Test subsequent presymptomatic members of a
family with an established mutation
d777 (d432–d1121) d125 (d77–d173) d95 (d71–d120) d997 (d579–d1415)
22. Counsel and arrange presymptomatic care for
members of a family with no established mutation
d759 (d415–d1103) d122 (d74–d171) d93 (d68–d118) d975 (d557–d1392)
Costs are rounded to the nearest d1 within each column. HNPCC¼hereditary nonpolyposis colorectal cancer; FAP or FAPC¼familial adenomatous polyposis coli.
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sTable 6 Workload units (WLUs) per molecular genetic test
Cancer and
mutations Type of analysis Molecular strategy WLU Staff Resources
Breast, ovarian or
breast ovarian
Mutation screening K Sample reception/DNA extraction 24 MT01 Lab
BRCA1/2 BRCA1:
K DGGE for exons 2–24 (45 fragments using MT
a
technology)
506 MT02 Lab
K Rearrangement analysis (dosage PCR) 120 MT02 Lab
K Sequence analysis of variants 320 B-grade 17 Lab and 0ffice
K Report 15 B-grade 17
BRCA2:
K DHPLC for exons 2–27 (40 fragments using MT
a
technology)
450 MT02 Lab
K Sequence analysis of variants 320 B-grade 17 Lab and office
K Report 15 B-grade 17
Presymptomatic
testing
K Sample reception/DNA extraction (duplicate
samples)
48 MT01 Lab
Sequence analysis of known mutation 440 B-grade 17 Lab and office
K Report 15 B-grade 17
HNPCC Mutation screening K Sample reception/DNA extraction 24 MT01 Lab
MLH1/MSH2 MLH1:
K Sequence analysis (19 fragments using MT
a
technology)
1520 MT02 Lab
MSH2:
K Sequence analysis (16 fragments using MT
a
technology)
1280 MT02 Lab
K Report 15 B-grade 17 Lab and office
Presymptomatic
testing
K Sample reception/DNA extraction (duplicate
samples)
48 MT01 Lab
K Sequence analysis of known mutation 440 B-grade 17 Lab and office
K Report 15 B-grade 17
FAP Mutation screening K Sample reception/DNA extraction 24 MT01 Lab
APC K APC sequence analysis (24 fragments using MT
a
technology)
1920 MT02 Lab
K Report 15 B-grade 17 Lab and office
Presymptomatic
testing
K Sample reception/DNA extraction (duplicate
samples)
48 MT01 Lab
K Sequence analysis of known mutation 440 B-grade 17 Lab and office
K Report 15 B-grade 17
Presymptomatic
testing
K Sample reception/DNA extraction (duplicate samples
plus family samples)
144 MT01 Lab
(Linkage analysis) K Polymorphic marker analysis (six samples for two
markers)
540 B-grade 17 Lab and office
K Report 60 B-grade 17
aWeighted WLUs for the use of medium throughput (MT) technology. HNPCC¼hereditary nonpolyposis colorectal cancer; FAP or FAPC¼familial adenomatous polyposis
coli.
Table 7 Molecular genetic testing consumables and unit costs
Method Components (supplier) Cost per unit (d)
DNA extraction Whatman kit (Abbott Diagnostics, Maidenhead, Berkshire, UK) d3.50
Polymerase chain reaction (PCR) K 166mM (NH4)2SO4, 670mM Tris-HCl (pH 8.3), 37mM M MgCl2, 850mg/ml BSA d0.66
K 0.5mM forward and reverse primers (synthetic DNA molecules – Invitrogen, Paisley, Scotland, UK)
K 0.5U Taq polymerase (Invitrogen, Paisley, Scotland, UK)
K 750mM deoxyribonucleotides (Invitrogen, Paisley, Scotland, UK)
K 100ng genomic DNA
Gel electrophoresis K DGGE (9% (37.1 acyrlamide:1 bis-acrylamide) polyacrylamide, 0–100% formamide, 1 TAE) d0.24
K DHPLC (Transgenomics, Crewe, Cheshire, UK)
K Automated DNA sequencer (Applied Biosystems, Foster City, CA, USA)
Sequence analysis K ABI BigDye3.0 kit (Applied Biosystems, Foster City, CA, USA) d3.19
Licence fee K Payable for use of patented PCR technology (Roche Diagnostics, Lewes, East Sussex, UK) d2.70 (single test)
d5.60 (multiple
tests)
Costs exclude value added tax.
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sTable 8 Laboratory costs per molecular genetic test
Test
Consumables
(extract blood sample)
Laboratory
consumables Labour Capital Overheads Total
Breast, ovarian or breast ovarian – Mutation screening d0.19 d138.67 d560.76 d239.76 d110.48 d1049.86
Breast, ovarian or breast ovarian – Presymptomatic testing d0.38 d59.63 d271.58 d90.96 d41.42 d463.97
HNPCC – Mutation screening d0.19 d338.46 d464.38 d278.81 d130.33 d1212.17
HNPCC – Presymptomatic testing d0.38 d59.63 d271.58 d90.96 d41.42 d463.97
FAP – Mutation screening d0.19 d235.45 d323.58 d192.16 d89.81 d841.19
FAP – Presymptomatic testing d0.38 d46.06 d271.58 d90.96 d41.42 d450.40
FAP – Presymptomatic testing (Linkage analysis) d0.38 d46.06 d371.04 d120.14 d54.69 d592.31
All consumables include VAT. HNPCC¼hereditary nonpolyposis colorectal cancer; FAP or FAPC¼familial adenomatous polyposis coli.
Table 9 Total cost per event pathway
Sensitivity
Event pathway
Counselling and
administrative
costs (min–max)
Laboratory
costs
Total cost
(min–max)
25% of time on
indirect work
(min–max)
75% of time on
indirect work (min–max)
1. Family history questionnaire
not returned
d16 (d14–d17) d0.00 d16 (d14–d17) d13 (d12) d41 (d36–d47)
2. Inappropriate referral d98 (d51–d144) d0.00 d98 (d51–d144) d85 (d44–d125) d260 (d137–d384)
3. Moderate risk – breast cancer d97 (d40–d153) d0.00 d97 (d40–d153) d84 (d35–d133) d258 (d107–d408)
4. Moderate risk – colorectal cancer d98 (d51–d144) d0.00 d98 (d51–d144) d85 (d44–d125 d260 (d137–d384)
5. Moderate Risk – ovarian or
breast ovarian cancer
a
d151 (d79–d223) d0.00 d151 (d79–d223) d131 (d69–d194) d400 (d208–d592)
High risk – colorectal (HNPCC)
6. Test cancer-affected relative
(mutation found) and test
presymptomatic patient
b
d1396 (d803–d1988) d1676 d3072 (d2479–d3664) d2887.79 (d2,373.76–d3401.82) d5371.49 (d3799.73–d6943.25)
7. Test cancer-affected relative
(no mutation found) and do not
test presymptomatic patient
b
d826 (d466–d1186) d1213 d2039 (d1678–d2399) d1929.86 (d1617.39–d2242.32) d3397.61 (d2442.01–d4353.24)
8. Test subsequent presymptomatic
members of a family with an
established mutation
(MLH1/ MSH2 mutation in family)
d997 (d579–d1415) d464 d1461 (d1043–d1879) d1329.32 (d966.80–d1691.86) d3104.66 (d1996.40–d4212.92)
9. Counsel and arrange
presymptomatic care for members
of a family with no established
mutation
d975 (d557–d1392) d0.00 d975 (d557–d1392) d846 (d484–d1208) d2581 (d1475–d3688)
High risk – colorectal (FAP)
10. Test cancer-affected relative
(mutation found) and test
presymptomatic patient
b
d1396 (d803–d1988) d1292 d2687 (d2095–d3280) d2503 (d1989–d3017) d4987 (d3415–d6559)
11. Test cancer-affected relative
(no mutation found) and do not
test presymptomatic patient
b
d826 (d466–d1186) d842 d1668 (d1307–d2028) d1558.88 (d1246.41–d1871.34) d3026.63 (d2071.03–d3982.26)
12. Test subsequent presymptomatic
members of a family with an
established mutation
(using linkage testing)
d997 (d579–d1415) d592 d1589 (d1171–d2007) d1458 (d1095–d1820) d3233 (d2125–d4341)
13. Test subsequent presymptomatic
members of a family with
an established mutation
(using sequence analysis)
d997 (d579–d1415) d450 d1447 (d1029–d1865) d1316 (d953–d1678) d3091 (d1983–d4199)
14. Counsel and arrange presymptomatic
care for members of a family
with no established mutation
d975 (d557–d1392) d0.00 d975 (d557–d1392) d846 (d484–d1208) d2,581 (Ł1475–d3688)
High risk – breast (BRCA1/2)
15. Test cancer-affected relative
(mutation found) and test
presymptomatic patient
b
d996 (d437–d1555) d1514 d2510 (d1950–d3069) d2379 (d1894–d2864) d4143 (d2660–d5626)
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sstrategy that can significantly enhance detection and survival
chances for them.
An inappropriate referral is as expensive as a referral for a
patient at moderate risk of developing breast or colorectal cancer.
This is a result of obtaining medical records to check the family
history reported by the patient. On average, more patient records
are checked for this group of patients and as a result more labour
costs are incurred. The discrepancy between actual and reported
family history usually stems from a patient misidentifying the
location of cancer for a deceased relative or a relative they are no
longer in contact with.
As is the case with moderate risk patients, variation in the mean
costs associated with referrals for patients at high risk is a result of
variation in the procedures involved with each cancer type. A
single counsellor deals with patients at high risk of breast cancer.
Patients at risk of developing ovarian or colorectal cancer receive
all of their counselling sessions with two counsellors, a consultant
(MC21/02 or MC21/04) and the team leader (NPU/04) or the
service and practice development coordinator (NP51/05), and a
cancer-affected relative will receive one of their two counselling
sessions with two counsellors. Two counsellors are used due to
the complexity of the issues to be addressed and to aid the training
of counsellors. In addition, the laboratory costs differ for
all molecular genetic tests with the exception of presymptomatic
screening (sequence analysis) for breast and/or ovarian mutations
(BRCA1 and BRCA2) and HNPCC mutations (MLH1 and MSH2).
Sensitivity analysis revealed that the event pathways with
no laboratory testing were most sensitive to change in the
percentage of work time devoted to indirect patient contact.
This was a result of labour costs contributing less to the laboratory
costs than to clinical and administrative costs as can be seen from
Tables 5 and 8.
In interpreting the results of this study readers should bear
in mind the following factors. Firstly, the measurement of labour
for clinical and administrative tasks was based upon the stated
responses of seven members of staff to an administered
questionnaire. Obviously the more time consuming and expensive
option of gathering revealed stochastic data by means of a
time and motion exercise on all 22 event pathways for a large
cohort of patients would yield incontrovertible data. It would
also be preferable to conduct such a study at multiple sites
using the same clinical and laboratory protocols, allowing
differences by cancer genetic centre to be allowed for. Secondly,
due to the small sample size in this study, 10 members of staff, it
was not possible to conduct statistical analysis upon the
cost estimates. Thirdly, the costs in this study are based upon a
service working at full capacity, which is the case for the Cardiff
clinic of the CGSW since its inception in 1999. In the unlikely event
that demand for cancer genetic services declines (Ponder,
1999), the cost per patient using each event pathway
would obviously rise in accordance with the decline in demand.
Fourthly, all mutation screening in this study was conducted
using medium throughput technology (see Table 6). Smaller
laboratories that do not have access to such labour saving devises
would obviously incur greater labour and capital costs per test
than the Cardiff laboratory. Conversely, a laboratory with more
medium throughput devises, for examlple, for presymptomatic
tests or technological developments reducing labour input, would
Table 9 (Continued)
Sensitivity
Event pathway
Counselling and
administrative
costs (min–max)
Laboratory
costs
Total cost
(min–max)
25% of time on
indirect work
(min–max)
75% of time on
indirect work (min–max)
16. Test cancer-affected relative
(no mutation found) and
do not test presymptomatic patient
b
d614 (d283–d946) d1050 d1665 (d1333–d1996) d1584 (d1296–d1872) d2671 (d1791–d3551)
17. Test subsequent presymptomatic
members of a family with
an established mutation
d688 (d288–d1087) d464 d1152 (d752–d1551) d1061 (d715–d1408) d2280 (d1221–d3340)
18. Counsel and arrange presymptomatic
care for members of a family with no
established mutation
d675 (d279–d1070) d0.00 d675 (d279–d1070) d586 (d243–d929) d1782 (d733–d2831)
High risk – ovarian or
breast ovarian (BRCA1/2)
c
19. Test cancer-affected relative
(mutation found) and test
presymptomatic patient
b
d1396 (d803–d1988) d1514 d2909 (d2317–d3502) d2725 (d2211–d3240) d5209 (d3637–d6781)
20. Test cancer-affected relative
(no mutation found) and do not
test presymptomatic patient
b
d826 (d466–d1186) d1050 d1876 (d1516–d2236) d1768 (d1455–d2080) d3235 (d2280–d4191)
21. Test subsequent
presymptomatic members
of a family with an
established mutation
d997 (d579–d1415) d464 d1461 (d1043–d1879) d1329 (d967–d1692) d3105 (d1996–d4213)
22. Counsel and arrange
presymptomatic care for members
of a family with no
established mutation
d975 (d557–d1392) d0.00 d975 (d557–d1392) d846 (d484–d1208) d2581 (d1475–d3688)
Costs are rounded to the nearest d1 within each column. HNPCC¼hereditary nonpolyposis colorectal cancer; FAP or FAPC¼familial adenomatous polyposis coli.
aJoint
ovarian clinic for moderate risk ovarian/breast ovarian: min ¼d27.26, max ¼d51.44, mean ¼ d39.35.
bIf the cancer-affected relative of a high-risk patient is too ill to attend the
cancer genetics clinic, a genetic counsellor will make a home visit. A home visit would result in a mean net increase of d36.60 to the cost of testing a cancer-affected relative and
the presymptomatic patient.
cJoint ovarian clinic for high-risk ovarian/breast ovarian: min ¼d36.75, max ¼d110.25, mean ¼ d73.50.
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sresult in a reduction in labour costs. Despite the limitations noted
above, we believe that the cost estimates derived in this study are
representative of the protocol used and are generalisable to similar
services and settings.
Lerman (1997) has questioned the appropriateness of counsel-
ling protocols such as the one in this study as they are derived
from Huntington’s disease protocols. Protocols with extensive
pretest assessment were initially designed to identify depression
and suicidal potential. Brown and Kessler (1995, 1996) and Lerman
have called for economic analysis in this field to identify the most
cost-effective method of delivering cancer genetic services,
including a comparison of delivering cancer genetic services by
different clinicians and in different settings. We are wholeheartedly
in support of a comprehensive assessment of all competing
protocols in terms of costs, health outcomes and patient utility in
terms of health outcomes, nonhealth outcomes and process. The
health outcomes and utility results gathered in parallel with this
costing will be published in detail elsewhere.
In conclusion, the cost of providing cancer genetic services to
patients at increased risk of developing breast, ovarian, breast
ovarian or colorectal cancer (HNPCC or FAP) are substantial,
particularly in the case of high-risk presymptomatic patients from
families approaching cancer genetic services for the first time at
d2,510–d3,072 (event pathways 6, 10, 15 and 19). The most
expensive element of all 22 event pathways was labour costs.
Labour costs were dependent upon the grade of staff used to
conduct a task, how quickly the task was performed, was there a
need to conduct tasks such as obtain medical records and check
them, the number of counsellors used (two counsellors were used
to counsel high-risk ovarian/breast ovarian and colorectal cancer
patients) and the proportion of staff time devoted to indirect
patient contact such as audit, clinical governance and adminis-
trative requests. With the growing demand for cancer genetic
services and the growing number of national and regional cancer
genetic centers, there is a need for the protocols being used to be
thoroughly evaluated in terms of costs and outcomes. We present
this manuscript as a first step in the economic evaluation of
alternative contemporary methods of delivering cancer genetic
services.
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